the remaining positives, page-25

40% drop on the news is way way overdone.
The drug has satisfied both primary point and safety, it is the interaction with BI's other drug MOA-B that cause the decision of discontinuation.
The key point is: the drug is working very well but just not with BI's scope.
Even if BI decide not to proceed the second (diabete) after the P2a mid next year, PXS will has the option to bring the drug to other Pharmas for new developments.
So the drug is NOT dead.
I don't see the reason of 40% drop on that news only, and I expect Gary is in the crisis control to speed up the LOXL2 deal
Strong rebounce on the way